Related Experiment Videos
[The era of myocardial reperfusion]
1Servicio de Cardiología, Hospital General de la Vall d'Hebron, Barcelona.
Insights
Myocardial reperfusion therapy saves lives in acute myocardial infarction. Early treatment and improved methods are crucial, as current therapies have limitations in recanalization and reocclusion rates.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Myocardial reperfusion is a critical therapy for acute myocardial infarction (AMI).
- Scientific advancements in ischemia, coronary occlusion, and fibrinolysis drive its success.
- Despite benefits, current reperfusion strategies face challenges with efficacy and timing.
Purpose of the Study:
- To review the current state of myocardial reperfusion therapy in AMI.
- To identify limitations and areas for improvement in existing reperfusion methods.
- To explore potential benefits of reperfusion beyond myocardial salvage.
Main Methods:
- Review of scientific literature on myocardial ischemia and reperfusion.
- Analysis of clinical trial data on fibrinolytic and mechanical reperfusion therapies.
- Discussion of pre-hospital treatment strategies and their cost-effectiveness.
Main Results:
- Fibrinolytic therapy reduces mortality by 30% but has limitations.
- Reperfusion benefits may extend to ventricular remodeling and arrhythmias.
- Thrombolysis fails in 20-30% of patients; reocclusion occurs in 10-15%.
Conclusions:
- Optimal reperfusion therapy requires early intervention.
- Mechanical angioplasty is an alternative but not universally established.
- Further research is needed to optimize reperfusion in AMI.
Abstract:
Myocardial reperfusion is the single most useful therapeutic approach in patients with acute myocardial infarction. The thousands of lives saved each year by this treatment are the result of scientific progress in very different areas, including the biopathology of myocardial ischemia and reperfusion, the mechanisms of coronary occlusion, the pharmacology of the fibrinolytic system, and clinical research. The 30% reduction in mortality achieved by fibrinolytic treatment in patients with acute myocardial infarction does not fit, apparently, with the short time-window during which restoration of blood flow results in significant myocardial salvage in animal models with few collaterals. This discrepancy could be due to the protective effect of intermittent coronary occlusions immediately preceding stable occlusive thrombosis (ischemic preconditioning), or to other possible beneficial effects of reperfusion independent of myocardial salvage, as limitation of ventricular remodelling or reduction of the risk of cardiac rupture or severe arrhythmias. Clearly, the best approach to increase the beneficial effects of reperfusion therapy is to perform it as early as possible; the cost-effectiveness of pre-hospital treatment strategies is now under investigation. In the other hand, current reperfusion therapy cannot be considered optimal. Thrombolytic agents fail to achieve recanalization of the infarct related vessel in 20-30% of patients, and 10-15% of the successfully opened arteries present early reocclusion. In certain subgroups of patients, such in those with cardiogenic shock, failure rate is higher. Mechanical recanalization by "direct" angioplasty represent an alternative reperfusion method, which utility has been established in certain circumstances only. So, well in the "reperfusion era", many questions remain open.(ABSTRACT TRUNCATED AT 250 WORDS)